Assessing the Significance of RSV Vaccines in Adult Populations

Ryan Haumschild, PharmD, MS, MBA, leads a panel of medical experts in a discussion regarding adult RSV vaccination.

Key opinion leaders discuss risk factors for RSV and patient populations most susceptible to the disease.

The panel explores RSV infection susceptibility and transmission.

Mary Bridgeman, PharmD, BCPS, BCGP, FASCP, Adam C. Welch, PharmD, MBA, FAPhA, and Christina Madison, PharmD, FCCP, AAHIVP, discuss the testing and treatment strategies for RSV.

Dr Madison provides insights on the importance of and strategies for raising awareness to adult RSV vaccines.

Drs Bridgeman and Welch highlight cost and resource impacts in health care systems driven by RSV.

A panel of experts discuss RSV vaccination in adults.

Medical experts discuss the lack of RSV treatment leading to the importance of immunization.

Financial, clinical, and social barriers to adult RSV vaccination are explored.

Dr Haumschild drives a discussion around what pharmacies and health care systems can expect from RSV infections in adult patient populations.

Electronic health record utilization and financial considerations for RSV vaccines in adults are overviewed by Drs Madison and Welch.

Key opinion leaders traverse the challenges associated with vaccine hesitancy.

With their closing thoughts, the panelists explore unmet needs in the landscape of adult RSV vaccination.